Cenrifki

tolebrutinib · Sanofi Winthrop Industrie
AUTHORISED IN THE EU

What Cenrifki is used for

Cenrifki is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) without relapses in the last 2 years.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Cenrifki
Active substance
tolebrutinib
Disease area
Multiple Sclerosis, Chronic Progressive
Medicine group
Selective immunosuppressants
ATC code
L04AA62
Marketing authorisation holder
Sanofi Winthrop Industrie
Authorised in the EU since
2026

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Cenrifki used for?

Cenrifki is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) without relapses in the last 2 years.

What is the active substance in Cenrifki?

Cenrifki contains tolebrutinib.

Who makes Cenrifki?

The EU marketing authorisation holder is Sanofi Winthrop Industrie.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.